There is no information on the effect of MAO-B inhibitors on PD cardiovascular dysfunction, however according to the European label, the use of selegiline in combination with levodopa has a number of contraindications limiting its clinical use, such as hypertension, tachycardia, cardiac arrhythmia, and severe coronary heart disease [37]. This evidence concerns the gene MAOB and hypertensive disorder.